Nimesulide: Advantages, Perspective Use During the Coronavirus Pandemic
https://doi.org/10.31550/1727-2378-2022-21-2-80-83
Abstract
Objective of the Review: To discuss the specific properties of Nimesulide and its use in COVID-19.
Key Points. A significant advantage of Nimesulide is a very rapid analgesic effect, due to rapid and meal-independent absorption in the gastrointestinal tract, almost complete binding to blood albumin, equally rapid achievement of the maximum concentration both in synovial fluid and blood. Now we have some data on the promising use of Nimesulide for COVID-19 management.
Conclusion. An idea that Nimesulide should be among the medicinal products undergoing assessment for the use for COVID-19 management, seems rather rational. Although it is not clear whether such studies will be conducted and what their outcome will be, selection of Nimesulide as one of the primary drugs for pain management and inflammation therapy both by medical professionals and patients is not by chance; it is completely informed and justified.
References
1. Rainsford K.D. Current status of the therapeutic uses and actions of the preferential cyclo-oxygenase-2 NSAID, nimesulide. Inflammopharmacology. 2006; 14(3–4): 120–37. DOI: 10.1007/s10787-006-1505-9
2. Bennett A. Nimesulide a well established cyclooxygenase-2 inhibitor with many other pharmacological properties relevant to inflammatory diseases. In: Vein J.R., Botting R.M., eds. Therapeutic roles of selective COX-2 inhibitors. William Harvey Press; 2001: 524–40.
3. Елисеев М.С. Алгоритм диагностики и лечения подагры. Русский медицинский журнал. 2015; 23(7): 410–14. [Eliseev M.S. Algorithm for gout diagnostics and management. RMJ. 2015; 23(7): 410–14. (in Russian)]
4. Кудаева Ф.М., Барскова В.Г., Насонова В.А. Сравнение скоро сти наступления противовоспалительного и аналгетитического эффекта таблетированных нимесулидов и диклофенака натрия при подагрическом артрите: рандомизированное исследование. Научно-практическая ревматология. 2008; 46(1): 55–9. [Kudaeva F.M., Barskova V.G., Nasonova V.A. Comparison of speed of anti-inflammatory and analgesic effect appearance of nimesulid and diclofenac sodium tablets in gout arthritis: a randomized study. Rheumatology Science and Practice. 2008; 46(1): 55–9. (in Russian)]. DOI: 10.14412/1995-4484-2008-854
5. Davis R., Brodgen R.N. Nimesulide: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1994; 48(3): 431–54. DOI: 10.2165/00003495-199448030-00009
6. Bernareggi A. Clinical pharmacokinetics of nimesulide. Clin. Pharmacokinet. 1998; 35(4): 247–74. DOI: 10.2165/00003088-199835040-00001
7. Rainsford K.D., ed. Nimesulide — actions and uses. Basel: Birkhäuser; 2005. 433 р. DOI: 10.1007/3-7643-7410-1
8. Барскова В.Г., Елисеев М.С., Кудаева Ф.М. Нимесулид. Терапевтический архив. 2007; 79(8): 92–7. [Barskova V.G., Eliseev M.S., Kudaeva F.M. Nimesulide. Terapevticheskii Arkhiv (Ter. Arkh.). 2007; 79(8): 92–7. (in Russian)]
9. Kress H.G., Baltov A., Basiński A. et al. Acute pain: a multifaceted challenge — the role of nimesulide. Curr. Med. Res. Opin. 2016; 32(1): 23–36. DOI: 10.1185/03007995.2015.1100986
10. Кнорринг Г.Ю., Верткин А.Л. «Правильный» нимесулид: взгляд фармаколога. Доктор.Ру. 2019; 10(165): 38–42. [Knorring G.Yu., Vyortkin A.L. ‘Correct’ nimesulide: a pharmacologist's opinion. Doctor.Ru. 2019; 10(165): 38–42. (in Russian)]. DOI: 10.31550/1727-2378-2019-165-10-38-42
11. Paudel S., Aryal B. Exploration of self-medication practice in Pokhara valley of Nepal. BMC Public Health. 2020; 20(1): 714. DOI: 10.1186/s12889-020-08860-w
12. Барскова В.Г., Гильмутдинова Е.В. Применение нимесулида при подагрическом артрите: эффективность, безопасность и приверженность больных к лечению. Справочник поликлинического врача. 2007; 7: 40–5. [Barskova V.G., Gilmutdinova E.V. Use of Nimesulide in gouty arthritis: efficiency, safety and compliance. Spravochnik polikliniches kogo vracha. 2007; 7: 40–5. (in Russian)]
13. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т. и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015; 9(1): 4–23. [Karateev A.E., Nasonov E.L., Ivashkin V.T. et al. Clinical guidelines “Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice”. Modern Rheumatology Journal. 2015; 9(1): 4–23. (in Russian)]. DOI: 10.14412/1996-7012-2015-1-4-23
14. Wong A.Y., MacKenna B., Morton C.E. et al. Use of non-steroidal antiinflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Ann. Rheum. Dis. 2021; 80(7): 943–51. DOI: 10.1136/annrheumdis-2020-219517
15. Bruce E., Barlow-Pay F., Short R. et al. Prior routine use of non steroidal antiinflammatory drugs (NSAIDs) and important outcomes in hospitalised patients with COVID-19. J. Clin. Med. 2020; 9(8): 2586. DOI: 10.3390/jcm9082586
16. Li W., Moore M.J., Vasilieva N. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003; 426(6965): 450–4. DOI: 10.1038/nature02145
17. Hoffmann M., Kleine-Weber H., Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181(2): 271–80.e8. DOI: 10.1016/j.cell.2020.02.052
18. Мухачёв Е.В, Сирецкая Т.В., Цветков А.О. Анализ специфи ческих спектральных характеристик s-белков коронави русов, рассчитанных по модели резонансного распознава ния. Прикладные проблемы безопасности технических и биотехнических систем. 2020; 2: 24–32. [Mukhachev E.V., Siretckaia T.V., Tsvetkov A.O. The analysis of specific spectral characteristics s-proteins coronaviruses calculated on the resonant recognition model. Prikladnye problemy bezopasnosti tekhnicheskih i biotekhnicheskih sistem. 2020; 2: 24–32. (in Russian)]. DOI 10.25960/2500-2538.2020.2.24.
19. Харченко Е.П. Коронавирус SARS-Cov-2: особенности структурных белков, контагиозность и возможные иммунные коллизии. Эпидемиология и вакцинопрофилактика. 2020; 19(2): 13–30. [Kharchenko E.Р. The coronavirus SARS-Cov-2: the characteristics of structural proteins, contagiousness, and possible immune collisions. Epidemiology and Vaccinal Prevention. 2020; 19(2): 13–30. (in Russian)]. DOI: 10.31631/2073-3046-2020-19-2-13-30
20. Ge X.Y., Li J.L., Yang X.L. et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013; 503(7477): 535–8. DOI: 10.1038/nature12711
21. Menachery V.D., Dinnon K.H. 3rd, Yount B.L. Jr et al. Trypsin treatment unlocks barrier for zoonotic bat coronavirus infection. J. Virol. 2020; 94(5): e01774–19. DOI: 10.1128/JVI.01774-19
22. Cava C., Bertoli G., Castiglioni I. In silico discovery of candidate drugs against COVID-19. Viruses. 2020; 12(4): 404. DOI: 10.3390/v12040404
23. Scalise M., Indiveri C. Repurposing nimesulide, a potent inhibitor of the B0AT1 subunit of the SARS-CoV-2 receptor, as a therapeutic adjuvant of COVID-19. SLAS Discov. 2020; 25(10): 1171–3. DOI: 10.1177/2472555220934421
24. Yan R., Zhang Y., Li Y. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020; 367(6485): 1444–8. DOI: 10.1126/science.abb2762
25. Pochini L., Seidita A., Sensi C. et al. Nimesulide binding site in the B0AT1 (SLC6A19) amino acid transporter. Mechanism of inhibition revealed by proteoliposome transport assay and molecular modelling. Biochem. Pharmacol. 2014; 89(3): 422–30. DOI: 10.1016/j.bcp.2014.03.014
26. Yang Z., Ji W., Li M. et al. Protective effect of nimesulide on acute lung injury in mice with severe acute pancreatitis. Am. J. Transl. Res. 2019; 11(9): 6024–31.
Review
For citations:
Eliseev M.S. Nimesulide: Advantages, Perspective Use During the Coronavirus Pandemic. Title. 2022;21(2):80-83. (In Russ.) https://doi.org/10.31550/1727-2378-2022-21-2-80-83
Views:
18
Email this article 